This article is mentioned in:

Introduction

Esophageal cancer is one of the most common cancer types with the 11th highest morbidity rate and 6th highest mortality rate globally, and caused ~439,000 mortalities in 2015 (1). The incidence of esophageal cancer notably varies among different regions, with eastern Asia and eastern and southern Africa exhibiting the highest rates of incidence and western Africa exhibiting the lowest rates in 2012 (1,2). In China, the estimated esophageal cancer cases and mortalities were 477,000 and 375,000, respectively, in 2015 (3). Although the morbidity rate of esophageal cancer has decreased in middle and high-middle sociodemographic index countries between 2005 and 2015, the mortality rate remains high due to the poor prognosis (1,4). The combination of surgical resection with chemotherapy or radiotherapy has been used to treat esophageal cancer, however, it has been reported that between 2003 and 2014 the 5-year survival rate remained <20% in China, USA and Europe (4,5). For these reasons, it is urgent to develop novel therapeutic agents to treat esophageal cancer.

Traditional Chinese herbal medicine (CHM) has been used to treat various cancer types, including non-small cell lung cancer (6), colorectal cancer (7), hepatocellular carcinoma (8). Recently, the clinical trials reported that the combination of CHM with chemotherapy or radiotherapy not only demonstrated a number of benefits on the quality of life and alleviating side effects induced by chemotherapy or radiotherapy (9,10), but also improved the survival rate of patients with non-small cell lung, liver, gastric, colorectal, nasopharyngeal or cervical cancer (9). However, there is conflicting evidence regarding the efficacy of CHM treatment on esophageal cancer (10,11). Numerous studies determined that a number of herbal medicines or components could inhibit the growth of esophageal cancer cells in vitro and in vivo, including Andrographis paniculata (12,13), Daikenchuto (14), icariin (15), Rosa Roxburghii Tratt and Fagopyrum Cymosum (16), Jaridonin (17), Marsdenia tenacissima (18), OP16 (a novel ent-kaurene diterpenoid) (19), Qigesan (20) and Tonglian decoction (21). Cistanche is a type of CHM and exerts various biological functions, including anti-oxidation, anti-inflammation and neuroprotection (22,23). Our previous study demonstrated that Cistanche tubulosa phenylethanoid glycosides (CTPG) could suppress the growth of melanoma B16-F10 cells in vitro and in vivo (24). However, the poor water solubility of CTPG previously used limits the drug development (24). Therefore, water-soluble CTPG (CTPG-W) was used and the antitumor effect on esophageal cancer cells (Eca-109) was investigated. It was determined that CTPG-W could dose-dependently inhibit the viability of Eca-109 cells through the induction of apoptosis via a mitochondrial-dependent pathway.

Materials and methods

Animals

Female C57BL/6 mice (6–8 weeks, ~25 g) were purchased from the Beijing Laboratory Animal Research Center (Beijing, China) and housed in the temperature-controlled (25°C), light-cycled (12/12) Animal Facility of Xinjiang University (Urumqi, China). All animals received pathogen-free water and food.

Cell line and culture

The human esophageal carcinoma cell line (Eca-109) was preserved by the Xinjiang Key Laboratory of Biological Resources and Genetic Engineering (College of Life Science and Technology, Xinjiang University, Urumqi, China) and cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; MRC, EN MOASAI Biological Technology Co., Ltd, Jiangsu, China), 1% L-glutamine (100 mM), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO2.

High performance liquid chromatography (HPLC)

CTPG-W (cat. no. SGJG20170410) was purchased from Shanghai Upbio Tech Co., Ltd. (Shanghai, China). The major compounds of CTPG were qualified and quantified by HPLC according to our previous study (24). Briefly, HPLC was conducted on a ZORBAX SB-C18 Column (250×4.6 mm; 5 µm) at 30°C and eluted with 0.2% formic acid solution and a gradient of methanol starting at 23%, as 1 ml was added every min for 45 min until reaching 31%. A total of 10 µl sample was injected and detected at 330 nm. The echinacoside standard was purchased from Shanghai Baoban Biotech Co., Ltd. (Shanghai, China), and acteoside standard was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The standards were used to analyze the components of CTPG-W.

MTT assay

Cell proliferation was measured with an MTT assay. Eca-109 cells were inoculated into 96-well plates at a density of 5×103 cells in 100 µl RPMI-1640 medium/well and cultured at 37°C for 24 h, then treated by different concentrations (0, 200, 400, 600 and 800 µg/ml) of CTPG-W or 0.4% dimethyl sulfoxide (DMSO) for 24, 48 and 72 h. DMSO was used as solvent control (800 µg/ml CTPG-W containing 0.4% DMSO). Cisplatin (20 µg/ml) was used as the positive control. Subsequently, the supernatant was discarded following centrifugation at 225 x g for 5 min at room temperature and 100 µl MTT solution (0.5 mg/ml in RPMI-1640 medium without FBS) was added to each well and incubated at 37°C for 3 h. The formed formazan crystals were dissolved in 200 µl DMSO. The optical density (OD) values were measured at a wavelength of 490 nm by a 96-well microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The relative cell viability was calculated according to the formula: Cell viability (%)=(ODtreated/ODuntreated)×100%. The morphology of Eca-109 cells was observed with an inverted fluorescence microscope (magnification, ×200) (Nikon Eclipse Ti-E; Nikon Corporation, Tokyo, Japan).

For the proliferation of splenocytes, C57BL/6 mice were euthanized by cervical dislocation and spleens were isolated. The single cell suspension was made and splenocytes were seeded into 96-well plates at a density of 1×105 cells/well in 100 µl RPMI-1640 medium, and then treated with different concentrations (0, 200, 400, 600 and 800 µg/ml) of CTPG-W for 24, 48 and 72 h at 37°C with 5% CO2. The proliferation of splenocytes was measured by MTT assay, according to the aforementioned protocol. Stimulatory index=ODtreated/ODuntreated.

Measurement of apoptosis and the cell cycle

Eca-109 cells were cultured in 60 mm dishes at a density of 2.5×105 cells/dish for 24 h and treated with different concentrations (0, 200, 400, 600 and 800 µg/ml) of CTPG-W or 0.4% DMSO for 24 h at 37°C with 5% CO2. Cells were collected and stained with an Annexin V-fluorescein isothiocyanate (FITC)/Propidium iodide (PI) Apoptosis Detection kit (Shanghai Shengsheng Biotechnology Co., Ltd., Shanghai, China), according to the manufacturer's protocols. Samples were collected by flow cytometry (BD FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA) and analyzed by FlowJo 7.6 (Tree Star, Inc., Ashland, OR, USA). To analyze the effect of CTPG-W on the cell cycle, 2.5×105 Eca-109 cells were seeded in 60 mm culture dishes and treated with CTPG-W (0, 100, 200 and 400 µg/ml) or 0.4% DMSO for 24 h at 37°C with 5% CO2. All cells were harvested and washed twice with ice-cold PBS (Gibco; Thermo Fisher Scientific, Inc.), then fixed in 70% ice-cold ethanol at 4°C for 30 min. Following washing twice with ice-cold PBS, cells were resuspended in 300 µl PI/RNase staining buffer (BD Biosciences, San Jose, CA, USA) for 10 min at room temperature. The cell cycle distribution was analyzed with the ModFit LT 3.0 software by flow cytometry (BD FACSCalibur).

Analysis of mitochondrial membrane potential (Δψm) and reactive oxygen species (ROS)

To analyze the Δψm, Eca-109 cells were treated with CTPG-W (0, 400, 600 and 800 µg/ml) or 0.4% DMSO for 24 h at 37°C with 5% CO2, and stained with the Mitochondrial membrane potential assay kit with JC-1 (Beyotime Institute of Biotechnology, Shanghai, China), according to the manufacturer's protocol, for 20 min at 37°C. Following washing twice with JC-1 washing buffer (Beyotime Institute of Biotechnology), samples were resuspended with 300 µl JC-1 washing buffer and analyzed by flow cytometry (BD FACSCalibur). The fluorescence of JC-1 dye in Eca-109 cells was also observed with an inverted fluorescence microscope (magnification, ×200; Nikon Eclipse Ti-E). For analysis of ROS, Eca-109 cells were treated with CTPG-W (0, 400, 600 and 800 µg/ml) for 2, 4, 6, 12 and 24 h, and stained with Reactive Oxygen Species Assay kit (Beyotime Institute of Biotechnology), according to the manufacturer's protocol, for 20 min at 37°C. Following washing three times with ice-cold PBS, samples were collected by flow cytometry (BD FACSCalibur) and analyzed by FlowJo 7.6 software.

2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity

The free radical scavenging activity of CTPG-W was determined with a DPPH free radical assay according to the published protocol with a minor modification, as methanol was substituted with ethanol to dissolve DPPH (25,26). For steady state measurements, 150 µl DPPH (100 mmol/l) in ethanol was mixed with different concentrations of CTPG-W (25, 50, 75, 100, 250, 300, 400, 500 and 600 µg/ml) in 50 µl PBS, and incubated in the dark for 30 min at room temperature. The absorbance at 517 nm was detected in the presence and absence of CTPG-W. A total of 50 µl Vitamin C was used as the positive control. The DPPH radical scavenging activity was calculated using the formula: Scavenging (%)=[1-(Asample-Ablank)/A0] ×100, where Ablank is the absorbance of the control (without DPPH), Asample is the absorbance of the sample and A0 is the absorbance of PBS with DPPH.

Western blot analysis

Eca-109 cells were treated with CTPG-W (0, 200, 600 µg/ml) or 0.4% DMSO for 24 h at 37°C with 5% CO2. Following washing twice with PBS, cells were lysed in Radioimmunoprecipitation Assay Lysis buffer (Beijing ComWin Biotech Co., Ltd., Beijing, China) for 20 min on ice. After centrifugation at 10,000 x g for 10 min at 4°C, the supernatants were collected, and protein concentrations were detected with a bicinchoninic acid kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols. Western blot analysis was conducted according to our previous description (24). The antibodies against caspase-7 (cat. no. D120077), caspase-8 (cat. no. D155240), caspase-9 (cat. no. D220078), B-cell lymphoma-2 (Bcl-2)-associated X (Bax) (cat. no. D220073) and Bcl-2 (cat. no. D260117), and anti-mouse IgG-horseradish peroxidase (HRP) (cat. no. D111050) and anti-rabbit IgG-HRP (cat. no. D110058) were purchased from BBI Life Sciences (Shanghai, China). The antibodies against caspase-3 (cat. no. E-AB-10050) and active caspase-3 (cat. no. E-AB-22115) were bought from Elabscience (Wuhan, China). Other antibodies against caspase-7 (cat. no. 9492), poly (ADP-ribose) polymerase (PARP) (cat. no. 9542), cytochrome c (cat. no. AC909), c-Jun NH2-terminal kinase (JNK) (cat. no. 9252S) and β-actin (cat. no. 58169) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). All primary and secondary antibodies were diluted at 1:1,000. The primary antibodies were incubated at 4°C overnight and the secondary antibodies were incubated at 37°C for 1 h. The target proteins were detected using enhanced chemiluminescence assay kit (Beyotime Institute of Biotechnology), according to the manufacturer's protocol.

Statistical analysis

Statistical significance was calculated by one-way analysis of variance with Tukey's post hoc test and results were analyzed using GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA) among the treatment and control groups. All data were presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

CTPG-W suppresses the growth of Eca-109 cells

The components of CTPG-W were qualified and quantified by HPLC (Fig. 1), which were compared with the standards of echinacoside and acteoside. According to the peak retention times and the peak areas, CTPG-W contained 39.16% of echinacoside and 2.44% of acteoside. Firstly, the effect of CTPG-W on the viability of Eca-109 cells was determined with an MTT assay. CTPG-W was dissolved in DMSO at 200 mg/ml and diluted with RPMI-1640 medium containing 10% heat-inactivated FBS to indicated concentrations. Eca-109 cells were treated with CTPG-W and cell viability was analyzed with an MTT assay at the indicated time points. CTPG-W treatment significantly reduced the viability of Eca-109 cells in a dose- and time-dependent manner (P<0.001; Fig. 2A). The morphology of Eca-109 cells was observed with an inverted fluorescence microscope (magnification, ×200) following CTPG-W treatment for 24 h, which changed notably in a dose-dependent manner, with the cells shrinking and becoming round following CTPG-W treatment (Fig. 2B). These results indicate that CTPG-W suppresses the growth of Eca-109 cells. The effect of CTPG-W on the proliferation of splenocytes was also detected with an MTT assay. CTPG-W significantly promoted the proliferation of splenocytes in a dose-dependent manner (Fig. 2C), indicating that it has no cytotoxic effect on splenocytes.

Figure 1. The qualify control of CTPG-W. The components of CTPG-W were qualitatively and quantitatively analyzed by high performance liquid chromatography and compared with the standards of echinacoside and acteoside. CTPG-W, water-soluble phenylethanoid glycosides of C. tubulosa.

Figure 2. The effect of CTPG-W on the growth of Eca-109 cells and splenocytes. (A) Eca-109 cells were treated by different concentrations of CTPG-W for 24, 48 and 72 h, and then cell viability was detected with an MTT assay. (B) The morphological changes of Eca-109 cells upon CTPG-W treatment at 24 h. (C) Splenocytes of C57BL/6 mice were treated with different concentrations of CTPG-W for 24, 48 and 72 h, and then the proliferation was analyzed with an MTT assay. **P<0.01 and ***P<0.001, compared with the control. CTPG-W, water-soluble phenylethanoid glycosides of C. tubulosa.

CTPG-W induces apoptosis in Eca-109 cells

To investigate whether CTPG-W suppressed the growth of Eca-109 cells through the induction of apoptosis or necrosis, cells were treated with different concentrations of CTPG-W. After 24 h, the apoptosis and necrosis of Eca-109 cells were detected with Annexin V/PI staining. As depicted in Fig. 3A, Annexin V−/PI+ cells were gated as necrotic cells, and Annexin V+/PI+ and Annexin V+/PI− cells were gated as apoptotic cells. CTPG-W primarily induced the apoptosis of Eca-109 cells in a dose-dependent manner, although the necrotic Eca-109 cells also increased significantly under the treatment of 600 and 800 µg/ml CTPG-W (P<0.001 at 600 µg/ml and P<0.05 at 800 µg/ml). Consistently, the levels of pro-apoptotic Bax and anti-apoptotic Bcl-2 in Eca-109 cells were upregulated and downregulated, respectively, upon CTPG-W treatment (Fig. 3B). The results indicated that CTPG-W primarily inhibited the growth of Eca-109 cells through the induction of apoptosis.

Figure 3. The apoptosis of Eca-109 cells induced by CTPG-W. Cells were treated with different concentrations of CTPG-W for 24 h. (A) The apoptotic and necrotic Eca-109 cells were analyzed by flow cytometry. The upper panel depicts the individual dot plots and the lower panel depicts the summary data. *P<0.05 and ***P<0.001, compared with the control. (B) Total protein was isolated and the expression levels of Bax and Bcl-2 were detected with western blot analysis. Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X; DMSO, dimethyl sulfoxide; CTPG-W, water-soluble phenylethanoid glycosides of C. tubulosa.

CTPG-W induces cell cycle arrest at the S phase in Eca-109 cells

Disturbance of the cancer cell cycle will suppress cell growth and promote apoptosis (27). The distribution of the cell cycle in Eca-109 cells was detected with PI staining following CTPG-W treatment for 24 h. It was observed that cells in the S phase increased and cells in the G0/G1 phases indicated an overall significant decrease upon CTPG-W treatment (P<0.05; Fig. 4), indicating that CTPG-W arrests the Eca-109 cell cycle at the S phase.

Figure 4. The effect of CTPG-W on cell cycle distribution in Eca-109 cells. Different concentrations of CTPG-W were used to treat Eca-109 cells for 24 h and cell cycle distribution was analyzed by flow cytometry. *P<0.05 and **P<0.01, compared with the control. DMSO, dimethyl sulfoxide; CTPG-W, water-soluble phenylethanoid glycosides of C. tubulosa.

CTPG-W decreases Δψm and induces the release of cytochrome c. Apoptosis can be induced by a mitochondrial-dependent pathway (28,29). The pro- and anti-apoptotic members of the BCL-2 protein family serve important roles in the regulation of mitochondrial membrane integrity (30,31). Following CTPG-W treatment for 24 h, the Δψm was assessed using JC-1 staining. JC-1 aggregate (red fluorescence detected in FL-2) will disintegrate into monomer (green fluorescence detected in FL-1) when Δψm is reducing (32). As depicted in Fig. 5A, the frequencies of FL-1+FL-2−/+ cells increased significantly in a dose-dependent manner, indicating that the Δψm of Eca-109 cells decreased. The fluorescence changes in Eca-109 cells were also observed with an inverted fluorescence microscope (Fig. 5B). With the increasing concentrations of CTPG-W, the red fluorescence decreased and the green fluorescence increased, which is consistent with the data from flow cytometry. It was also observed that the level of cytochrome c in cytosol was notably increased (Fig. 5C), which is a result of a reduction of Δψm. This reinforces the conclusion drawn from the increased count of FL-1+FL-2−/+ cells that Δψm decreased as a result of CTPG-W treatment. It has reported that JNK can regulate the activation of the BCL-2 protein family causing the release of cytochrome c (33–35). It was also determined that the level of JNK was notably upregulated following CTPG-W treatment (Fig. 5C). The results indicated that CTPG-W may induce the apoptosis of Eca-109 cells through a mitochondrial-dependent pathway.

Figure 5. The reduction of Δψm and upregulation of cytochrome c and JNK. Eca-109 cells were treated with different concentrations of CTPG-W for 24 h. (A) Δψm was detected by JC-1 staining and samples were analyzed by flow cytometry. The individual dot plots depict the changes of JC-1 fluorescence. The frequencies of FL-1+FL-2−/+ cells are depicted in the lower panel. ***P<0.001, compared with the control. (B) The changes of JC-1 fluorescence were observed with an inverted fluorescence microscope. (C) The levels of cytochrome c and JNK were detected with western blot analysis. The different bands of JNK represent 54 and 46 kDa proteins. DMSO, dimethyl sulfoxide; CTPG-W, water-soluble phenylethanoid glycosides of C. tubulosa; JNK, c-Jun NH2-terminal kinase.

The effect of CTPG-W on intracellular ROS generation

ROS could reduce Δψm to induce apoptosis (36). To investigate whether CTPG-W can increase ROS production, Eca-109 cells were treated with different concentrations of CTPG-W. Cells were collected at the indicated time points and stained with DCFH-DA. The production of intracellular ROS in Eca-109 cells was determined by flow cytometry. As depicted in Fig. 6A, 800 µg/ml CTPG-W significantly increased ROS production from 2–6 h, and decreased from 12–24 h. Additionally, 400 µg/ml CTPG-W significantly increased ROS production from 12–24 h. Furthermore, 200 µg/ml CTPG-W did not notably alter ROS production. The dynamic changes of ROS production may be associated with Eca-109 cell apoptosis. It was also determined that CTPG-W had free radical scavenging activity (Fig. 6B), which may be associated with the decreased ROS production in Eca-109 cells treated with 800 µg/ml CTPG-W after 12 h.

Figure 6. The levels of ROS in Eca-109 cells upon CTPG-W treatment and the antioxidant activity of CTPG-W. (A) Eca-109 cells were treated with different concentrations of CTPG-W and the levels of ROS were analyzed by flow cytometry at indicated time points. *P<0.05, **P<0.01 and ***P<0.001, compared with the control. (B) The free radical scavenging activity of CTPG-W was determined with a 2,2-diphenyl-1-picrylhydrazyl assay. CTPG-W, water-soluble phenylethanoid glycosides of C. tubulosa; ROS, reactive oxygen species; MFI, mean fluorescence intensity.

CTPG-W upregulates the activity of caspase-3, caspase-7, caspase-9 and PARP

The release of cytochrome c due to Δψm reduction could activate the caspase proteases to induce apoptosis (29,30,37). Following CTPG-W treatment for 24 h, the activation of caspase-3, 7, 8, 9 and PARP was detected by western blot analysis. Compared with the control, the levels of cleaved-caspase-9, cleaved-caspase-7, cleaved-caspase-3 and cleaved-PARP, but not the levels of cleaved-caspase-8, were upregulated by CTPG treatment in a dose-dependent manner (Fig. 7). These results indicated that CTPG-W reduced Δψm and promoted cytochrome c release to activate caspases that induce the apoptosis of Eca-109 cells.

Figure 7. The levels of cleaved-caspases and cleaved-PARP following CTPG-W treatment. Proteins were isolated from Eca-109 cells treated with CTPG-W for 24 h and the levels of cleaved-caspases and cleaved-PARP were detected with western blot analysis. DMSO, dimethyl sulfoxide; CTPG-W, water-soluble phenylethanoid glycosides of C. tubulosa; PARP, poly (ADP-ribose) polymerase.

Discussion

Traditional CHM could induce apoptosis of esophageal cancer cells through different pathways, including the extrinsic death receptor, intrinsic mitochondrial and endoplasmic reticulum stress pathways (29). Our previous study demonstrated that CTPG, as the major component of C. tubulosa, inhibited the growth of melanoma B16-F10 cells through the induction of apoptosis via a mitochondrial-dependent pathway (24). In the present study, the antitumor effect of CTPG-W on Eca-109 cells was investigated and it was determined that CTPG-W suppressed the growth of Eca-109 cells, induced apoptosis and cell cycle arrest, reduced Δψm, increased the release of cytochrome c and activated caspases. CTPG and CTPG-W could induce the apoptosis and cell cycle arrest in cancer cells. However, the accurate mechanisms are different due to the different components of CTPG (26.64% echinacoside, 10.19% acteoside and 1.71% isoacteoside) and CTPG-W (39.16% echinacoside and 2.44% acteoside). CTPG arrested B16-F10 cells at the G0/G1 phases, but CTPG-W arrested Eca-109 cells at the S phase (24). ROS production was dose-dependently increased by CTPG, but it indicated a change in a time-dependent manner by high dose of CTPG-W, which increased significantly at the beginning of CTPG-W treatment (2–6 h) and decreased significantly after 12 h, compared with the control. A possible reason is that the major component of CTPG-W is echinacoside. A number of studies reported that echinacoside could inhibit ROS production and ROS-induced apoptosis to exert its neuroprotective and anti-aging effects (38–40). Similarly, the free radical scavenging activity was observed in the present study. Therefore, it was speculated that some components, including verbascoside, iso-verbascoside and salidroside in a high dose of CTPG-W might immediately induce ROS generation to cause apoptosis of Eca-109 cells (41,42), and then ROS was scavenged by echinacoside. Another possible reason for the differences in ROS production by CTPG and CTPG-W is that different cell lines were used in this study and previous study (24). Dong et al (43) reported that echinacoside could induce the apoptosis of human SW480 colorectal cancer cells through the generation of oxidative DNA damages without increased ROS levels.

CTPG-W treatment reduced Δψm and caused the release of cytochrome c, which promotes the cleavage of caspase-9 (28). Consistently, the levels of cleaved-caspase-9 were upregulated by CTPG-W treatment. Subsequently, the active caspase-9 can activate caspase-3 to induce apoptosis (44). The levels of cleaved-caspase-3 were also upregulated by CTPG-W treatment. However, caspase-8 was not activated by CTPG-W, indicating that the extrinsic death receptor pathway was not involved in the apoptosis induced by CTPG-W. These observations indicate that CTPG-W induces apoptosis of Eca-109 cells through the activation of a mitochondrial-dependent pathway.

PARP serves important roles in the genomic stability and can be cleaved by the active caspases, particularly caspase-3 and −7 (45). It was determined that CTPG-W treatment activated caspase-3 and −7, which may cleave PARP to inhibit DNA repair and cause apoptosis.

CTPG-W also dose- and time-dependently suppresses the growth of human hepatocellular carcinoma BEL-7404 cells (unpublished data). Although CTPG-W inhibits the growth of Eca-109 and BEL-7404 cells, it promotes the proliferation of splenocytes, which may be due to the content of polysaccharides (~50%) in CTPG-W (46). Similarly, a number of studies have reported that polysaccharides can promote the proliferation of splenocytes (46–49). In the mouse model, it was determined that CTPG-W significantly increased the spleen index, compared with the control group, but did not affect the body weight and the other organ indexes including heart, liver, kidney and lung (unpublished data), indicating that CTPG-W has no cytotoxic effect on normal cells.

Collectively, the data indicated that CTPG-W inhibits the growth of Eca-109 cells by induction of apoptosis via a mitochondrial-dependent pathway.

Acknowledgements

The authors would like to thank Dr Jianhua Yang (Baylor College of Medicine) for polishing the manuscript.

Funding

This study was supported by the 13th Five-Year Plan for Key Discipline Biology Bidding Project (grant no. 17SDKD0202), Xinjiang Normal University and Key Laboratory of Special Environment Biodiversity Application and Regulation in Xinjiang (grant no. XJTSWZ-2017-04) to JL and the Chinese National Natural Science Foundation Grant (grant no. 31760260) to XW.

Availability of data and materials

Data and materials used and analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

CF, AA, YY and QC performed the experiments. LX, JLv and XW analyzed the data and the prepared figures. JinyuL and JinyaoL designed the project and wrote the manuscript.

Ethics approval and consent to participate

All animal experiments were approved by the Committee on the Ethics of Animal Experiments of Xinjiang Key Laboratory of Biological Resources and Genetic Engineering (approval, no. BRGE-AE001; Xinjiang University).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Glossary

Abbreviations

Abbreviations:

References